

Curriculum vitae

April 10, 2019

Name: **Laura Suter-Dick**
Contact: laura.suterdick@fhnw.ch

Career History:

2012-present Professor for Molecular Toxicology at the School of Life Sciences (Institute of Chemistry and Bioanalytics), University of Applied Sciences Northwestern Switzerland (FHNW), Switzerland.

1997-2012 Research scientist and manager (vice-director) in Non-clinical Safety at F. Hoffmann-La Roche AG, Basel, Switzerland.

1994-1997 Post-doctoral position in Reproductive Toxicology, Sandoz AG/Novartis Pharma, Basel, Switzerland.

1991-1994 Ph.D. student in Fertility Control and Hormone Therapy, Schering AG, Berlin, Germany.

Education:

2015-ongoing Didactic courses (four completed) towards the "Hochschuldidaktik Sammelzertifikat" from the University of Basel.

From 2014 European Registered Toxicologist (ERT), granted by Eurotox through the Swiss Register for Toxicology.

2000-2006 Leadership skills courses at F. Hoffmann-La Roche, as well as "Mobilizing Leaders" and "Leadership & Teamwork" at IMD Business School (Lausanne, Switzerland).

1994-1997 Post-doctoral position in Reproductive Toxicology, Sandoz AG, Basel, Switzerland.

1991-1994 Ph.D. in Biological Sciences, Freie Universitaet Berlin and Schering AG, Berlin, Germany.

1985-1990 University Degree: Master in Biological Sciences, Universidad de Buenos Aires, Argentina.

1979-1984 High School Degree: Colegio Nacional de Buenos Aires, Argentina.

Selected research projects/grants:

CTI: 16856.1 PFLS-LS Establishment of a platform for the study of liver disease (fibrosis) in vitro; 2014, 18-months, CHF 241'810.

NC3R: Crack-it, nephroscreen; 2015, 36 months, CHF 429'000.

CTI: 25617.1 PFLS-LS Validation and optimization of a screening platform for the study of liver disease (fibrosis and NASH); 2017, 12 months, CHF 162'809.

CTI: 25720.1 PFLS-LS 3D human liver microtissue-based in vitro assay for predicting metabolic stability of low clearance compounds in pharmaceutical drug development; 2017, 12 months, CHF 187'776.

Eurostars: HepaPlate; 2016, 24 months, CHF 60'000.

SCAHT: Organotypical liver models for fibrosis; 2015, 36 months, CHF 199'500.

Several direct financed collaborative projects (industrial partners).

Additional activities & memberships:

President biotechnet Switzerland; 2017-present.

Swiss Centre for Applied Human Toxicology (SCHAT), Hepatotoxicity team; 2015- present.

European Expert Evaluator (EC FP7 and Horizon 2020); 2012- present.

Node representative at the 3RCC (3R-national competence center); 2017-present.

Member of ESTIV, Swiss Toxicology Society and Eurotox.

Selected Publications Full list available at Research Gate (h-index: 26):

https://www.researchgate.net/profile/Laura_Suter-Dick/publications:

1. Dieterle F, *et al.*. The PSTC Renal Biomarker Qualification Submission and FDA/EMA Decisions: Conclusions and Implications of First Formal Qualification Submission. *Nature Biotechnology* 28(5):455-62 (2010).
2. R. M. Kostadinova, F. Boess, D. R. Applegate, **L. Suter**, T. Weiser, T. Singer, B. A. Naughton, A. Roth. A Long-Term Three Dimensional Liver Co-Culture System for Improved Prediction of Clinically Relevant Drug-Induced Hepatotoxicity. *Toxicol. Applied Pharmacol*, 268: 1-16 (2013).
3. F. Boess, C. Bertinetti-Lapatki, S. Jensen-Zoffmann, C. George, T. Pfister, A. Roth, S.M.L. Lee, W. Thasler, T. Singer, **L. Suter**. Effects of GLP-1 R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man. *J. Mol Endocrinol*, 50: 325-336 (2013).
4. L. Bailey, L. Moreno, T. Manigold, H. Kropshofer, H. Hinton, T. Singer, **L. Suter**, T. T. Hansel and J. A. Mitchell. A simple whole blood bioassay to detect the propensity of biotherapeutic antibodies such as anti-CD28SA to cause a cytokine storm. *Journal of Pharmacological and Toxicological Methods*, 68: 231-239 (2013).
5. S. Kustermann, T. Manigold, C. Ploix, M. Skubatz, T. Heckel, H. Hinton, T. Weiser, T. Singer, **L. Suter**, A. Roth. A Real-time Impedance-Based Screening Assay for Drug-Induced Vascular Leakage. *Toxicol Sci.* 138(2):333-43 (2014).
6. Buness A, Roth A, Herrmann A, Schmitz O, Kamp H, Busch K, Suter L. Identification of metabolites, clinical chemistry markers and transcripts associated with hepatotoxicity. *PLOS One* 9 (5): e97249 (2014).
7. **L. Suter-Dick**, PM Alves, BJ Blaauboer, *et al.*. Stem cell derived (SCD) systems in toxicology assessment. *Stem Cells and Development*, Feb 2015. e-print.
8. MJ Wilmer, C. PingNg, HL Lanz, P Vulto, **L Suter-Dick** and R Masereeuw: Kidney-on-a-Chip Technology for Drug-Induced Nephrotoxicity Screening. *Trends in Biotechnology*, Vol. 34, No. 2 (2016).
9. F.A. Atienzar, E.A. Blomme, M. Chen, P. Hewitt, J. G. Kenna, G. Labbe, F. Moulin, F. Pognan, A.B. Roth, **L. Suter-Dick**, O. Ukairo, R. J. Weaver, Y. Will, D.M. Dambach: Key challenges and opportunities associated with the use of In vitro models to detect human DILI: Integrated risk assessment and mitigation plans. *BioMed Research International*:9737920 (2016).
10. V. Prestigiacomo, A. Weston, S. Messner, F. Lampart, **L. Suter-Dick**. Pro-Fibrotic Compounds Induce Stellate Cell Activation, ECM-Remodelling and Nrf2 Activation in a Human 3D-Multicellular Model of Liver Fibrosis. *PLOS One*, Jun 30;12 (2017).
11. Vriend J, Nieskens TTG, Vormann MK, van den Berge BT, van den Heuvel A, Russel FGM, *et al.* Screening of Drug-Transporter Interactions in a 3D Microfluidic Renal Proximal Tubule on a Chip. *Aaps j.* 2018;20(5):87.
12. Vormann MK, Gijzen L, Hutter S, Boot L, Nicolas A, van den Heuvel A, *et al.* Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal Tubules. *AAPS J.* 2018;20(5):90.
13. **Suter-Dick L**, Mauch L, Ramp D, Caj M, Vormann MK, Hutter S, *et al.* Combining Extracellular miRNA Determination with Microfluidic 3D Cell Cultures for the Assessment of Nephrotoxicity: a Proof of Concept Study. *Aaps j.* 2018;20(5):86.
14. V Prestigiacomo, **L. Suter-Dick**. Nrf2 protects stellate cells from Smad dependent cell activation. *PLOS One*, Jul 20;13 (2018).